Market Cap 45.87M
Revenue (ttm) 200,000.00
Net Income (ttm) -26.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,085.00%
Debt to Equity Ratio -0.22
Volume 124,900
Avg Vol 82,304
Day's Range N/A - N/A
Shares Out 12.85M
Stochastic %K 10%
Beta 0.95
Analysts Strong Sell
Price Target $32.00

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic...

Industry: Packaged Foods
Sector: Consumer Defensive
Phone: 801 676 9695
Website: clene.com
Address:
6550 South Millrock Drive, Suite G50, Salt Lake City, United States
faterepeat14
faterepeat14 Sep. 11 at 11:38 PM
$CLNN so frustrating price action
0 · Reply
neuroinvestor3
neuroinvestor3 Sep. 11 at 8:44 PM
$CLNN Why can't CLNN raise the $ to get through NDA/ALS P3? Strong balance sheet = investor confidence. Dilute and get it over with. We have about 6 or so months of cash runway?
0 · Reply
Woodman7
Woodman7 Sep. 11 at 12:11 PM
0 · Reply
faterepeat14
faterepeat14 Sep. 11 at 1:38 AM
$CLNN next Thursday may be ?
0 · Reply
Ravery
Ravery Sep. 11 at 12:32 AM
$CLNN short interest down about 40k from 8/15. It appears the stock is not being driven down by short sellers.
0 · Reply
paule815
paule815 Sep. 10 at 10:37 AM
$CLNN It’s THURSDAY! You know we get wild in here on THURSDAY! Who is getting tacos later or a nice steak. If you are a vegetarian then I guess Tofu? Wake yo booty up and lock in. I’ll buy if you do! 🌮💎🌮💎🌮💎🌮💎🌮💎🌮
1 · Reply
Ultrasound
Ultrasound Sep. 9 at 10:42 PM
$CLNN 2 years ago I did a screenshot (below)of Analysts projections when it was trading at $4.16 - they had PT's of +380%-2,000%. Although they've tightened their PT between +430%-1,200% they have been wrong for 2 years straight (even the pump in Oct'25 didn't come close to price targets). Why do ppl buy into Analysts PT and how do they get away with this year after year?
0 · Reply
faterepeat14
faterepeat14 Sep. 9 at 8:14 PM
$CLNN Thursday is coming !
0 · Reply
LXP
LXP Sep. 9 at 5:04 PM
0 · Reply
Woodman7
Woodman7 Sep. 9 at 2:47 PM
$BIIB $CLNN $QNTM $RHHBY $SNY From the article: “Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. These findings will be included in Clene’s planned New Drug Application (“NDA”) seeking accelerated approval and are intended to address the questions raised by the U.S. Food and Drug Administration (“FDA”) during a March 2026 Type C meeting. At that meeting, the FDA acknowledged that NfL, a recognized blood marker of nerve-cell injury, has established prognostic value in amyotrophic lateral sclerosis (“ALS”) and could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.”
0 · Reply
Latest News on CLNN
Clene to Present at Upcoming September Investor Conferences

Sep 3, 2026, 8:00 AM EDT - 10 days ago

Clene to Present at Upcoming September Investor Conferences


Clene Transcript: Emerging Growth Conference

Aug 19, 2026, 3:10 PM EDT - 24 days ago

Clene Transcript: Emerging Growth Conference


Clene to Present at the Emerging Growth Conference

Aug 17, 2026, 8:30 AM EDT - 27 days ago

Clene to Present at the Emerging Growth Conference


Clene reports Q2 EPS ($1.08), consensus (26c)

2026-08-16T13:18:33.000Z - 4 weeks ago

Clene reports Q2 EPS ($1.08), consensus (26c)


Clene Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

Clene Quarterly report: Q2 2026


Clene Earnings release: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

Clene Earnings release: Q2 2026


Clene to Present at The Canaccord 46th Annual Growth Conference

Jul 29, 2026, 8:30 AM EDT - 6 weeks ago

Clene to Present at The Canaccord 46th Annual Growth Conference


Clene reports Q1 EPS (69c), consensus (70c)

2026-05-14T16:30:10.000Z - 4 months ago

Clene reports Q1 EPS (69c), consensus (70c)


Clene Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 months ago

Clene Quarterly report: Q1 2026


Clene Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 months ago

Clene Earnings release: Q1 2026


Clene price target raised to $50 from $48 at Canaccord

2026-05-08T11:23:32.000Z - 4 months ago

Clene price target raised to $50 from $48 at Canaccord


Clene Transcript: Emerging Growth Conference 92

May 6, 2026, 3:25 PM EDT - 4 months ago

Clene Transcript: Emerging Growth Conference 92


Clene to Present at Upcoming May Conferences

May 5, 2026, 8:00 AM EDT - 4 months ago

Clene to Present at Upcoming May Conferences


Clene Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 5 months ago

Clene Proxy statement: Proxy filing


Clene Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 5 months ago

Clene Proxy statement: Proxy filing


Clene reports FY25 EPS ($2.65), consensus ($2.35)

2026-03-12T12:12:18.000Z - 6 months ago

Clene reports FY25 EPS ($2.65), consensus ($2.35)


Clene Annual report: Q4 2025

Mar 12, 2026, 8:00 AM EDT - 6 months ago

Clene Annual report: Q4 2025


Clene Annual report: Q4 2025

Mar 12, 2026, 8:00 AM EDT - 6 months ago

Clene Annual report: Q4 2025


Clene Earnings release: Q4 2025

Mar 12, 2026, 8:00 AM EDT - 6 months ago

Clene Earnings release: Q4 2025


Clene Transcript: Emerging Growth Virtual Conference

Feb 25, 2026, 1:45 PM EST - 6 months ago

Clene Transcript: Emerging Growth Virtual Conference


Clene issues letter to shareholders on CNM-Au8 2026 catalysts

2026-02-24T13:13:07.000Z - 6 months ago

Clene issues letter to shareholders on CNM-Au8 2026 catalysts


Clene Transcript: Emerging Growth Conference 89

Jan 21, 2026, 3:10 PM EST - 7 months ago

Clene Transcript: Emerging Growth Conference 89


Clene announces over $28M registered direct offering

2026-01-09T13:41:01.000Z - 8 months ago

Clene announces over $28M registered direct offering


Clene Announces Registered Direct Offering of Over $28 Million

Jan 9, 2026, 8:30 AM EST - 8 months ago

Clene Announces Registered Direct Offering of Over $28 Million


Clene Transcript: Emerging Growth Conference 88

Dec 10, 2025, 4:25 PM EST - 9 months ago

Clene Transcript: Emerging Growth Conference 88


Clene price target raised to $30 from $20 at Maxim

2025-12-03T18:15:36.000Z - 9 months ago

Clene price target raised to $30 from $20 at Maxim


Clene Transcript: Study Update

Dec 3, 2025, 8:30 AM EST - 9 months ago

Clene Transcript: Study Update


Clene Press release: Study Update

Dec 3, 2025, 8:30 AM EST - 9 months ago

Clene Press release: Study Update


Clene Slides: Study Update

Dec 3, 2025, 8:30 AM EST - 9 months ago

Clene Slides: Study Update


Clene to Provide CNM-Au8® ALS Program Update

Dec 2, 2025, 5:39 PM EST - 9 months ago

Clene to Provide CNM-Au8® ALS Program Update


Clene reports Q3 EPS (85c), consensus (56c)

2025-11-13T13:10:28.000Z - 10 months ago

Clene reports Q3 EPS (85c), consensus (56c)


Clene sees cash runway into 2Q26

2025-11-13T13:10:16.000Z - 10 months ago

Clene sees cash runway into 2Q26


Clene Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Clene Earnings release: Q3 2025


Clene Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Clene Quarterly report: Q3 2025


Clene Transcript: Emerging Growth Conference

Oct 23, 2025, 3:10 PM EDT - 10 months ago

Clene Transcript: Emerging Growth Conference


Clene announces presentation of combined REPAIR-MS results

2025-09-25T12:10:32.000Z - 11 months ago

Clene announces presentation of combined REPAIR-MS results


Clene price target lowered to $31 from $33 at Benchmark

2025-09-10T12:00:43.000Z - 1 year ago

Clene price target lowered to $31 from $33 at Benchmark


Clene Registration statement: Registration Filing

Sep 5, 2025, 8:00 AM EDT - 1 year ago

Clene Registration statement: Registration Filing


Clene Transcript: Emerging Growth Conference 85

Aug 20, 2025, 2:20 PM EDT - 1 year ago

Clene Transcript: Emerging Growth Conference 85


Clene price target lowered to $48 from $83 at Canaccord

2025-08-18T10:40:11.000Z - 1 year ago

Clene price target lowered to $48 from $83 at Canaccord


Clene Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Clene Earnings release: Q2 2025


Clene Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Clene Quarterly report: Q2 2025


Clene Transcript: Emerging Growth Conference 84

Jul 17, 2025, 3:10 PM EDT - 1 year ago

Clene Transcript: Emerging Growth Conference 84


Clene Transcript: Q2 Virtual Investor Summit Event

Jun 10, 2025, 1:00 PM EDT - 1 year ago

Clene Transcript: Q2 Virtual Investor Summit Event


Clene Transcript: Emerging Growth Conference 82

May 21, 2025, 3:10 PM EDT - 1 year ago

Clene Transcript: Emerging Growth Conference 82


Clene Slides: Investor Presentation

May 14, 2025, 7:00 AM EDT - 1 year ago

Clene Slides: Investor Presentation


Clene Earnings release: Q1 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Clene Earnings release: Q1 2025


Clene Quarterly report: Q1 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Clene Quarterly report: Q1 2025


Clene Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Clene Proxy statement: Proxy Filing


Clene Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Clene Proxy statement: Proxy Filing


Clene Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Clene Proxy statement: Proxy Filing


Clene Annual report: Q4 2024

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Clene Annual report: Q4 2024


Clene Earnings release: Q4 2024

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Clene Earnings release: Q4 2024


Clene Registration statement: Registration Filing

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Clene Registration statement: Registration Filing


Clene Transcript: 37th Annual ROTH Conference

Mar 18, 2025, 12:30 PM EDT - 1 year ago

Clene Transcript: 37th Annual ROTH Conference


Clene to Present at the 37TH Annual Roth Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Clene to Present at the 37TH Annual Roth Conference


Clene Registration statement: Registration Filing

Jan 24, 2025, 7:00 AM EST - 1 year ago

Clene Registration statement: Registration Filing


Clene Slides: Investor Presentation

Dec 10, 2024, 7:00 AM EST - 1 year ago

Clene Slides: Investor Presentation


Clene Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Clene Quarterly report: Q3 2024


Clene Earnings release: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Clene Earnings release: Q3 2024


Clene Registration statement: Registration Filing

Nov 13, 2024, 7:00 AM EST - 1 year ago

Clene Registration statement: Registration Filing


Clene Quarterly report: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Clene Quarterly report: Q2 2024


Clene Earnings release: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Clene Earnings release: Q2 2024


Clene Announces 1-for-20 Reverse Stock Split

Jul 9, 2024, 8:00 AM EDT - 2 years ago

Clene Announces 1-for-20 Reverse Stock Split


Clene Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Clene Quarterly report: Q1 2024


Clene Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Clene Earnings release: Q1 2024


Clene Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Clene Proxy statement: Proxy Filing


Clene Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Clene Proxy statement: Proxy Filing


Clene Proxy statement: Proxy Filing

Apr 5, 2024, 8:00 AM EDT - 2 years ago

Clene Proxy statement: Proxy Filing


Clene Annual report: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Clene Annual report: Q4 2023


Clene Earnings release: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Clene Earnings release: Q4 2023


faterepeat14
faterepeat14 Sep. 11 at 11:38 PM
$CLNN so frustrating price action
0 · Reply
neuroinvestor3
neuroinvestor3 Sep. 11 at 8:44 PM
$CLNN Why can't CLNN raise the $ to get through NDA/ALS P3? Strong balance sheet = investor confidence. Dilute and get it over with. We have about 6 or so months of cash runway?
0 · Reply
Woodman7
Woodman7 Sep. 11 at 12:11 PM
0 · Reply
faterepeat14
faterepeat14 Sep. 11 at 1:38 AM
$CLNN next Thursday may be ?
0 · Reply
Ravery
Ravery Sep. 11 at 12:32 AM
$CLNN short interest down about 40k from 8/15. It appears the stock is not being driven down by short sellers.
0 · Reply
paule815
paule815 Sep. 10 at 10:37 AM
$CLNN It’s THURSDAY! You know we get wild in here on THURSDAY! Who is getting tacos later or a nice steak. If you are a vegetarian then I guess Tofu? Wake yo booty up and lock in. I’ll buy if you do! 🌮💎🌮💎🌮💎🌮💎🌮💎🌮
1 · Reply
Ultrasound
Ultrasound Sep. 9 at 10:42 PM
$CLNN 2 years ago I did a screenshot (below)of Analysts projections when it was trading at $4.16 - they had PT's of +380%-2,000%. Although they've tightened their PT between +430%-1,200% they have been wrong for 2 years straight (even the pump in Oct'25 didn't come close to price targets). Why do ppl buy into Analysts PT and how do they get away with this year after year?
0 · Reply
faterepeat14
faterepeat14 Sep. 9 at 8:14 PM
$CLNN Thursday is coming !
0 · Reply
LXP
LXP Sep. 9 at 5:04 PM
0 · Reply
Woodman7
Woodman7 Sep. 9 at 2:47 PM
$BIIB $CLNN $QNTM $RHHBY $SNY From the article: “Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. These findings will be included in Clene’s planned New Drug Application (“NDA”) seeking accelerated approval and are intended to address the questions raised by the U.S. Food and Drug Administration (“FDA”) during a March 2026 Type C meeting. At that meeting, the FDA acknowledged that NfL, a recognized blood marker of nerve-cell injury, has established prognostic value in amyotrophic lateral sclerosis (“ALS”) and could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.”
0 · Reply
Ravery
Ravery Sep. 9 at 1:59 PM
$CLNN I also think it was a good chat. However he did not provide any clarity related to the cash runway question. I guess that is to be expected, however the true vagueness of what the 'modest' raise will look like, makes it difficult for investors to buy into the story. The only things that is clear is that cash will be needed and needed soon, likely even before we know if the nda is accepted or not. We may have to deal with more near term pain, but I still like the longer term prospects of this investment. I also liked the insight into how the company plans to launch IF the FDA gives them a thumbs up. That would help in trying to model cash burn if we get the approval. Good luck longs
1 · Reply
Mulhollandr
Mulhollandr Sep. 9 at 1:41 PM
$CLNN great moderator and Rob nailed the questions. IMO.
0 · Reply
faterepeat14
faterepeat14 Sep. 9 at 9:35 AM
$CLNN wow.. is everything alright? So much down , can’t even buy dip anymore. Why me, always.. :(
1 · Reply
Acx21
Acx21 Sep. 9 at 9:12 AM
$CLNN dont panic, it's not the first time CLNN share price is under extreme pressure. Let's see if management already got a solution for the financals at today's Cantor call. If not: Always focus on the things which made you become an investor - the story/the potential/the upside. These are still running great. Yes, the financals are concerning, yes the share price is annyoing. But did you invest for today's share price or did you invest for the things potentially coming in 2027? After all, I'm still pretty confident in the team, they will figure it out. As always at the stock market: Dont panic, use your brain also in red times
0 · Reply
josh77
josh77 Sep. 9 at 9:00 AM
$CLNN wow....wow...wow! That's all I can say.
0 · Reply
Mulhollandr
Mulhollandr Sep. 8 at 10:46 PM
$CLNN is it October yet?😒
0 · Reply
paule815
paule815 Sep. 8 at 4:01 PM
$CLNN I’m not sure what’s going on here. I saw good things. I know the lights are on and people are moving around. But this dip is not cool…
0 · Reply
josh77
josh77 Sep. 8 at 4:01 PM
$CLNN rather depressing to be honest...one day this will work 😪
0 · Reply
Ravery
Ravery Sep. 8 at 2:38 PM
$CLNN What we do not have in our favor is a management team that has much skin in the game. Will our CFO have shareholder interests in mind while he is working a deal to shore up the balance sheet? He has no skin in the game. No preservation of capital to be concerned with outside of options that were awarded to him.
0 · Reply
Sterling100
Sterling100 Sep. 8 at 2:28 PM
$CLNN trimming down 5-10% every week since FDA meeting announcement. More than 60% down and management doesn't have a money to buy some shares in the open market. Good job!
1 · Reply
faterepeat14
faterepeat14 Sep. 8 at 1:53 PM
$CLNN bottomed??
1 · Reply
NetworkNewsWire
NetworkNewsWire Sep. 8 at 1:04 PM
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach $QNTM $SNY $RHHBY $BIIB $CLNN https://ibn.fm/MrHnd
0 · Reply